Saturday, February 28, 2026

تقدم خدمة Lenovo الجديدة بنية تحتية دائمة العمل: خدمة Premier Support Plus for Servers والمدعومة بالدعم الاستباقي القائم على الذكاء الاصطناعي


(BUSINESS WIRE)-- أعلنت Lenovo اليوم عن توفر خدمة Lenovo Premier Support Plus for Servers، وهي عرض دعم متميز جديد مصمم لمساعدة المؤسسات على تقليل وقت التوقف عن العمل، وتبسيط عمليات تكنولوجيا المعلومات، والحفاظ على جاهزية البنية التحتية المهمة للمهام دائمًا. صُممت خدمة Premier Support Plus لبيئات العمل الدائمة في يومنا هذا، وهي تجمع بين الدعم الاستباقي والتنبئي المدعوم بالذكاء الاصطناعي، والصيانة الوقائية، والوصول على مدار الساعة إلى خبراء Lenovo، ومديري مشاركة الخدمة المخصصين لمساعدة المؤسسات على الانتقال من حل المشكلات برد الفعل إلى الرعاية الاستباقية للنظام.


مع استمرار توسع العمليات الرقمية وتزايد تعقيد بيئات البنية التحتية، تتعرض فرق تكنولوجيا المعلومات لضغوط متزايدة للحفاظ على وقت التشغيل مع إدارة الموارد المحدودة. يمكن أن تؤدي نماذج الدعم التقليدية والتفاعلية إلى انقطاعات طويلة الأمد، ومشاكل متكررة، وتكاليف لا يمكن التنبؤ بها. تعالج خدمة Lenovo Premier Support Plus for Servers هذه التحديات من خلال تحديد المشكلات المحتملة مبكرًا وحلها قبل أن تؤثر على العمليات التجارية.


قال John Stamer، نائب الرئيس والمدير العام لخدمات المنتجات والاستدامة العالمية في Lenovo: "من خلال خدمة Premier Support Plus for Servers، تساعد Lenovo العملاء على البقاء في طليعة مشكلات البنية التحتية المحتملة قبل أن تؤثر على الأعمال". "من خلال الجمع بين الذكاء التنبؤي والإشراف الخبير والاستجابة السريعة، فإننا نمكّن المؤسسات من حماية وقت التشغيل وتقليل المخاطر والتركيز على الابتكار".


تعد خدمة Premier Support Plus for Servers أعلى فئة من عروض الدعم التي تقدمها Lenovo لبيئات خوادم المؤسسات، وهي مبنية على أساس خدمة Lenovo Premier Support. تم تصميم الخدمة لخوادم Lenovo ThinkSystem وThinkAgile، وهي توفر دعمًا ذكيًا للمؤسسات التي تعتمد على التوافر المستمر. تتضمن القدرات الرئيسية لخدمة Lenovo Premier Support Plus for Servers ما يلي:


دعم استباقي وتنبئي مدعوم بالمراقبة القائمة على الذكاء الاصطناعي وأتمتة Call Home، والتي تكتشف المشكلات المحتملة مبكرًا وتبدأ تلقائيًا في فتح حالات الدعم وإرسال قطع الغيار.

صيانة وقائية من خلال لوحات معلومات الحالة الصحية، وفحوصات سلامة البرامج الثابتة، وتوجيهات الخبراء لتحسين سلامة النظام وموثوقيته وطول عمره.

مساعدة الخبراء على مدار الساعة مع هدف استجابة في الموقع خلال 4 ساعات للمشكلات الحرجة، مما يساعد في ضمان التعافي السريع وتقليل الاضطراب إلى أدنى حد.

مدير مشاركة خدمة مخصص من Lenovo يتولى مسؤولية التهيئة وإعداد التقارير المستمرة ومراجعات الخدمة المنتظمة، حيث يعمل كنقطة مساءلة واحدة.

الاحتفاظ بمحرك الأقراص، مما يتيح للعملاء الاحتفاظ بمحركات الأقراص المعطلة للحفاظ على التحكم في البيانات الحساسة وتلبية متطلبات الأمن والامتثال الداخلية.

تغطية الخدمات العالمية في أكثر من 75 سوقًا، مما يوفر دعمًا متسقًا على مستوى المؤسسات في جميع أنحاء العالم.

ويقول Rob Brothers، نائب رئيس الخدمات في IDC: "وفقًا لأبحاث IDC الأخيرة، يضع العملاء قدرًا مماثلاً من التركيز، إن لم يكن أكثر، على إمكانيات الخدمات كما هو الحال مع ميزات المنتج عند تقييم البائعين". "ليس المنتج فقط، بل التجربة المحيطة به هي التي تساعد العملاء على اختيار البائع المناسب لاحتياجاتهم. مع إضافة Premier Support Plus، تقوم Lenovo بتوسيع محفظة خدماتها، والتي تم تصميمها لتعزيز تجربة خادم Lenovo الشاملة".


بالنسبة للعملاء الذين لديهم بيئات حرجة للمهام حيث لا يكون وقت التوقف عن العمل خيارًا، تقدم Lenovo أيضًا خدمة إصلاح ملتزمة كإضافة اختيارية. توفر هذه الخدمة المحسنة التزامًا بالإصلاح في الموقع لمدة 6 ساعات، مما يوفر حلًا أسرع للاحتياجات التشغيلية الأكثر إلحاحًا.


تجمع Premier Support Plus بين الكشف التنبئي والصيانة الوقائية والتخطيط الموجه للحفاظ على البنية التحتية محسنة وجاهزة للتوسع. من خلال الإشراف المخصص على الحساب من قبل مدير مشاركة خدمة Lenovo، والتغطية العالمية، وضوابط الاحتفاظ بالبيانات عبر ميزة Keep Your Drive، يحصل العملاء على دعم ثابت وشفاف يمكنهم الوثوق به. من خلال نقل عبء المراقبة والصيانة والتصعيد إلى Lenovo، يمكن لفرق تكنولوجيا المعلومات قضاء وقت أقل في الاستجابة للمشكلات ووقتًا أطول في دفع المبادرات الاستراتيجية.


تعد خدمة Premier Support Plus for Servers جزءًا من محفظة خدمات Lenovo الأوسع، والتي تتضمن خدمات Lenovo Lifecycle Services المصممة لمساعدة العملاء على تخطيط البنية التحتية لتكنولوجيا المعلومات ونشرها وإدارتها وتحسينها وتطويرها بثقة.


 لمعرفة المزيد حول Lenovo Premier Support Plus for Servers، تفضل بزيارة: https://www.lenovo.com/us/en/services/support-services/premier-support-plus-for-infrastructure/.


 حول Lenovo


 تعد Lenovo شركة تكنولوجية عالمية تبلغ إيراداتها 69 مليار دولار أمريكي، وتحتل المرتبة رقم 196 في قائمة Fortune Global 500، وتخدم ملايين العملاء يوميًا في 180 سوقًا. ركزت Lenovo على رؤية جريئة لتقديم تقنية أكثر ذكاءً للجميع، وقد بنت على نجاحها كأكبر شركة للكمبيوتر الشخصي في العالم مع مجموعة كاملة من الأجهزة الممكّنة بالذكاء الاصطناعي، والجاهزة للذكاء الاصطناعي، والمحسّنة للذكاء الاصطناعي (أجهزة الكمبيوتر الشخصية، ومحطات العمل، والهواتف الذكية، والأجهزة اللوحية)، والبنية التحتية (الخادم، والتخزين، والحواسيب المتطورة، والحوسبة عالية الأداء، والبنية التحتية المحددة بالبرمجيات)، والبرامج، والحلول، والخدمات. يعمل استثمار Lenovo المستمر في الابتكار المتغير عالميًا على بناء مستقبل أكثر إنصافًا وجدير بالثقة وأكثر ذكاءً للجميع في كل مكان. Lenovo مدرجة في بورصة هونغ كونغ تحت اسم Lenovo Group Limited (بورصة هونج كونج تحت الرمز: 992) ‏(وأداة ADR تحت الرمز: LNVGY). لمعرفة المزيد، تفضل بزيارة https://www.lenovo.com، واقرأ آخر الأخبار من خلال StoryHub.


 إخلاء المسؤولية


 قد يختلف توفر خدمة Committed Service Repair ‏(CSR) حسب المنتج والموقع. يرجى الرجوع إلى Lenovo Locator Tool لمعرفة ما إذا كانت خدمة CSR متوفرة في موقعك.


 وقت الاستجابة هو هدف وليس التزامًا مضمونًا. لمزيدٍ من المعلومات، يُرجى الاطلاعُ على اتفاقية خدمات مركز بيانات Lenovo.


LENOVO وTHINKSYSTEM وTHINKAGILE هي علامات تجارية لشركة Lenovo. جميع العلامات التجارية الأخرى ملك لأصحابها. حقوق الطبع والنشر لعام 2026© لصالح Lenovo Group Limited. جميع الحقوق محفوظة.


إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.


 



الرابط الثابت

https://aetoswire.com/ar/news/544338341


جهات الاتصال

  Zeno Group لصالح Lenovo SSG


 البريد الإلكتروني: LenovoSSG@zenogroup.com  

تتعاون شركة .1089 Inc مع Price Forbes وSyndicate 1922 التابعة لشركة Oka-Lloyd's لإطلاق منتج رائد في السوق: إطار عمل تأمين أصول الكربون لقطاعي النقل والطاقة

 


 لندن وبولدر، كولورادو - الجمعة, 27. فبراير 2026 


يقدم البرنامج الجديد ضمانات تأمينية مخصصة وبنية تحتية لنقل الأصول غير قابلة للتغيير، بهدف تعزيز النضج المالي لأسواق الكربون العالمية، مما يتيح مشاركة واسعة النطاق في قطاعي النقل والطاقة، وهما القطاعان الأكثر انبعاثًا للكربون في العالم.

 

(BUSINESS WIRE)-- أعلنت شركة .1089 Inc، بالتعاون مع Price Forbes وOka، شركة تأمين الكربون، عن إطلاق أصل كربوني مؤمن عليه مصمم لتوفير ضمانات مؤسسية وهيكل مالي منضبط وسلامة بيانات قابلة للتحقق لأسواق الكربون.

يوفر الإطار تغطية مخاطر محددة لأصول الكربون للوقود المتقدم CX89 التابعة لشركة 1089، والمكتتبة من قبل Lloyd’s Syndicate 1922 والموضوعة بدعم من Price Forbes وOka. يقدم البرنامج حماية من الدرجة المؤسسية مصممة لمنع خسائر الأداء الناتجة عن تدهور الائتمان بين عمليتي التغليف والسك.

 شارك Luke Hanley، المؤسس والرئيس التنفيذي لشركة .1089 Inc، الأطروحة الأساسية للإطار العملي:

 "إن مستقبل أسواق الكربون لا يُبنى على التكفير عن الذنب البيئي. إنما يُبنى على المشاركة المنظمة التي توائم بين الحوافز المالية ونتائج إزالة الكربون".

 وأضاف Chris Slater، المؤسس والرئيس التنفيذي لشركة Oka: "افتقرت أسواق الكربون الطوعية سابقًا إلى البنية التحتية المالية المطلوبة لرأس المال المؤسسي. من خلال دمج تغطية مخاطر الإلغاء المحددة مباشرة في الأصل، فإننا نقدم اليقين وقوة الميزانية العمومية في الجوانب الأكثر أهمية. ويمثل هذا خطوة حاسمة نحو ترسيخ الكربون كفئة أصول قابلة للاستثمار والتأمين".

 يدمج الإطار التأمين المضمن، والإشراف على السجل، والمحاسبة الثابتة. تمكين المنظمات من معالجة الانبعاثات التشغيلية المرتبطة بالوقود عبر سلاسل التوريد وتحويل طلب السوق إلى حوافز مالية تدعم إنتاج الوقود منخفض الانبعاثات على نطاق واسع.

كما قال Hanley: "نظرًا لتعقيد أسواق الكربون العالمية، فمن العملي جلب التمويل إلى الكربون أكثر من العكس".

 أكد Spenser Lee، رئيس قسم الوساطة في Price Forbes، على أهمية هذه الخطوة قائلًا: "من خلال تأمين سعة Lloyd’s لتغطية الإبطال المدمجة، أنشأنا إطارًا شفافًا لنقل المخاطر يعزز السيولة وثقة المستثمرين. هذا هو نوع نهج الوساطة المنضبط الذي سيكون مطلوبًا مع نضج أسواق الكربون".

 تغطي أصول الكربون للوقود المتقدم CX89 انبعاثات النطاقات 1-3 في قطاعات النفط والغاز، ومراكز البيانات، والتصنيع، وشحن المركبات الكهربائية، وتوليد الطاقة، والتوزيع عبر قطاعات الطيران والسيارات والبحرية والسكك الحديدية.

 أصول الكربون للوقود المتقدم CX89 متاحة للشراء العالمي.

 يمكن للمنظمات والمؤسسات التي تسعى للحصول على أصول تعويض مرتبطة بالوقود أو تنويع المحفظة، بالإضافة إلى ممثلي وسائل الإعلام، توجيه الاستفسارات إلى 1089 على info@1089inc.com

شركة 1089 Inc. هي شركة متخصصة في البنية التحتية لأصول الكربون، وتقود تطور أسواق الكربون العالمية.

 www.1089inc.com

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260226012782/en

 


الرابط الثابت
https://www.aetoswire.com/ar/news/54434502

جهات الاتصال
Rhiannon O'Donnell

 info@1089inc.com

1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors

 LONDON & BOULDER, Colo. - Friday, 27. February 2026





New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy.

 

(BUSINESS WIRE)--1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets.

The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces institutional-grade protection designed to prevent performance losses resulting from credit degradation between wrapping and minting.

Luke Hanley, Founder and CEO of 1089 Inc., shared the framework’s core thesis:

“The future of carbon markets is not built on environmental penance. It is built on structured participation that aligns financial incentives with decarbonization outcomes."

Founder and CEO of Oka, Chris Slater, added, “Voluntary carbon markets have previously lacked the financial infrastructure required for institutional capital. By embedding defined invalidation risk coverage directly into the asset, we introduce certainty and balance sheet strength where it matters most. This represents a decisive step toward establishing carbon as an investable, insurable asset class.”

The framework integrates embedded insurance, registry oversight, and immutable accounting. Enabling organizations to address fuels-linked operational emissions across supply-chains and convert market demand into financial incentives supporting scaled low-emission fuel production.

"Given the complexity of global carbon markets, it's more practical to bring finance to carbon than the inverse," Hanley states.

Spenser Lee, Chief Brokering Officer of Price Forbes, emphasized the significance, “By securing Lloyd’s capacity for embedded invalidation coverage, we’ve created transparent risk-transfer framework enhancing liquidity and investor confidence. This is the kind of disciplined brokering approach that will be required as carbon markets mature.”

CX89 Advanced Fuels Carbon Assets address Scope 1-3 emissions across Oil & Gas, Data Centers, Manufacturing, EV-charging, Power Generation, and Distribution across Aviation, Automotive, Maritime, and Rail.

CX89 Advanced Fuels Carbon Assets are available for global purchase.

Organizations and institutions seeking fuel-linked offset assets or portfolio diversification, as well as media representatives, may direct enquiries to 1089 at info@1089inc.com

1089 Inc. is a carbon asset infrastructure company pioneering the evolution of global carbon markets.

www.1089inc.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226012782/en/


Permalink
https://www.aetoswire.com/en/news/2702202653570

Contacts
Rhiannon O'Donnell
info@1089inc.com

 

سامسونج تجعل الذكاء الاصطناعي أكثر سلاسة مع إطلاق أكثر Galaxy AI ذكاء حتى الآن

  قدّمت سامسونج سلسلة Galaxy S26 مع أكثر تجربة Galaxy AI ذكاء حتى الآن، والمصممة لتبسيط المهام اليومية المتكررة عبر تقليل عدد الخطوات الفاصلة بين الفكرة والتنفيذ. وتعمل التقنية بشكل استباقي وسلس بالنيابة عن المستخدمين وبناءً على حالة الاستخدام، لتزوّدهم بالدعم الملائم في اللحظة المناسبة، وتقوم بأتمتة المهام بأقل قدر ممكن من التدخل اليدوي. وبينما تتولى التقنية تنفيذ المهام في تطبيقات الخلفية، يمكن للمستخدمين التركيز بشكل أكبر على النتائج المتحققة.


 


كيف تساعد ميزة Now Nudge المستخدمين على مواصلة مهامهم دون تشتيت انتباههم؟


 


توفر ميزة Now Nudge اقتراحات ذكية وملائمة زمنياً لمساعدة المستخدمين على مواصلة مهامهم دون تشتيت انتباههم. وعلى سبيل المثال، إذا طلب أحد الأصدقاء صوراً لرحلة حديثة، يقترح جهاز Galaxy S26 تلقائياً الصور المناسبة من المعرض دون الحاجة للبحث داخل الألبومات أو التنقل بين التطبيقات. وعند استلام رسالة حول اجتماع ما، يمكن للجهاز التعرف على أحداث التقويم المرتبطة والتحقق من وجود أي تعارض زمني.


 


ما الذي تفعله Now Brief على Galaxy S26؟


 


تم تطوير ميزة Now Brief في سلسلة أجهزة Galaxy S26 لتعزيز قدراتها الاستباقية والمخصصة، حيث يمكنها الآن عرض رسائل تذكير في الوقت المناسب حول الأحداث المهمة، مثل الحجوزات ومواعيد السفر، وذلك بناءً على التفضيلات الشخصية للمستخدمين، لتساعدهم في تنظيم يومهم.


 


كيف تم تطوير Circle to Search على Galaxy S26؟


 


أصبحت عملية البحث عن المعلومات أسهل من أي وقت مضى. فقد تم تطوير ميزة دائرة البحث من جوجل لتحسين قدرتها على تحديد عناصر متعددة ضمن الصورة الواحدة، مما يتيح للمستخدمين استكشاف أجزاء متعددة من الصورة في وقت واحد. وإذا حاز مظهر معين على إعجابهم، يمكن للميزة تحديد جميع العناصر من السترة إلى الحذاء ضمن عملية بحث واحدة.


 


ما الجديد في Bixby على Galaxy S26؟


 


تدمج سلسلة Galaxy S26 النسخة المحدّثة من Bixby كوكيل محادثة مدعوم بالذكاء الاصطناعي، في أسهل تجربة لتواصل المستخدمين مع أجهزة جالاكسي على الإطلاق. وتضمن التحسينات الجديدة للمستخدمين تنقلاً سهلاً بين مزايا الجهاز وضبط الإعدادات بالاعتماد على اللغة الطبيعية، دون الحاجة لاستخدام مصطلحات أو أوامر محددة.


 


كيف يعمل Gemini وPerplexity على Galaxy S26؟


 


إلى جانب Bixby، تدمج أجهزة جالاكسي خياراتٍ إضافية من وكلاء الذكاء الاصطناعي، بما في ذلك Gemini وPerplexity. وبعد استكمال الإعدادات الخاصة بها على الجهاز، يمكن للمستخدمين تنفيذ المهام بضغطة زر واحدة أو من خلال الأوامر الصوتية. ويمكن لجهاز Galaxy S26 أيضاً تنفيذ مهام متعددة الخطوات في تطبيقات الخلفية لتبسيط العمليات بالنيابة عن المستخدمين. فعلى سبيل المثال، يتيح تطبيق Gemini إمكانية حجز سيارة أجرة بمجرد الطلب، ثم يقوم المستخدمون بمراجعة تفاصيل الحجز والضغط على زر التأكيد. وتدعم أدوات المساعدة هذه مجموعة واسعة من المهام مثل أنشطة البحث وتنفيذ المهام المعقدة بين التطبيقات المتعددة بكل سهولة من خلال أوامر مبسطة باللغة الطبيعية.



الرابط الثابت

https://www.aetoswire.com/ar/news/2702202653583


جهات الاتصال

سلام الأعور


Salam@gambit.ae

Samsung makes AI feel effortless with the debut of its most intuitive Galaxy AI experience yet

  Samsung has introduced the Galaxy S26 Series with the most intuitive Galaxy AI experience yet, designed to reduce the steps between intent and action. Built to work more proactively based on context, Galaxy AI aims to surface the right support at the right moment and complete tasks with minimal manual input, so users can focus on results while the technology works quietly in the background.



How does Now Nudge help users stay in the flow?


Now Nudge provides timely, relevant suggestions created to support what users are doing without distracting them. For example, if a friend asks for photos from a recent trip, Galaxy S26 can automatically suggest the relevant photos from Gallery instead of requiring a manual search through albums. If a message mentions a meeting, Galaxy S26 can recognize related Calendar entries and help check for conflicts.


What does Now Brief do on Galaxy S26?


On Galaxy S26, Now Brief is more proactive and personalized, surfacing timely reminders for important events such as reservations and travel updates, based on personal context, helping users stay organized throughout the day.


How is Circle to Search upgraded on Galaxy S26?


Circle to Search with Google on Galaxy S26 is upgraded with enhanced multi-object recognition, allowing users to explore multiple parts of an image at once. If a user spots a look they like, the experience can identify multiple items, such as a jacket and shoes, in a single search.


What is new about Bixby on Galaxy S26?


Galaxy S26 introduces an upgraded Bixby as a more conversational device agent, aiming to make it easier to navigate the device and adjust settings using natural language, without needing exact terminology or commands.


How do Gemini and Perplexity work on Galaxy S26?


Alongside Bixby, Galaxy S26 integrates a choice of agents, including Gemini and Perplexity. Once set up, tasks can be completed with a single button press or voice prompt, and Galaxy S26 can also handle multi-step tasks in the background. For example, with Gemini, booking a taxi can be as simple as asking, reviewing the details, and tapping confirm. These agents are made to support searching and completing complex tasks across apps through natural interaction.



Permalink

https://www.aetoswire.com/en/news/2702202653582


Contacts

Salam Faisal


salam@gambit.ae

New Lenovo Service Delivers Always-On Infrastructure: Premier Support Plus for Servers Powered by Proactive, AI-Driven Support

 


 (BUSINESS WIRE)--Lenovo today announced the availability of Lenovo Premier Support Plus for Servers, a new premium support offering designed to help enterprises reduce downtime, simplify IT operations, and keep mission-critical infrastructure always ready. Built for today’s always-on environments, Premier Support Plus combines AI-driven proactive and predictive support, preventative maintenance, 24/7 access to Lenovo experts, and designated Service Engagement Managers to help organizations move from reactive issue resolution to proactive system care.


As digital operations continue to expand and infrastructure environments grow more complex, IT teams are under increasing pressure to maintain uptime while managing limited resources. Traditional, reactive support models can lead to extended outages, repeated issues, and unpredictable costs. Lenovo Premier Support Plus for Servers addresses these challenges by identifying potential issues early and resolving them before they impact business operations.


“With Premier Support Plus for Servers, Lenovo is helping customers stay ahead of potential infrastructure issues before they affect the business,” said John Stamer, Vice President & GM, Global Product & Sustainability Services at Lenovo. “By combining predictive intelligence, expert oversight, and rapid response, we’re enabling organizations to protect uptime, reduce risk, and focus on innovation.”


Premier Support Plus for Servers is Lenovo’s highest-tier support offering for enterprise server environments, building on the foundation of Lenovo Premier Support. The service is designed for Lenovo ThinkSystem and ThinkAgile servers and delivers intelligent support for organizations that depend on continuous availability. Key capabilities of Lenovo Premier Support Plus for Servers include:


Proactive and predictive support powered by AI-driven monitoring and Call Home automation, which detects potential issues early and automatically initiates support cases and parts dispatch.

Preventative maintenance through wellness dashboards, firmware health checks, and expert guidance to improve system health, reliability, and longevity.

24/7 expert assistance with a 4-hour onsite response objective for critical issues, helping ensure faster recovery and minimal disruption.

A designated Lenovo Service Engagement Manager who provides onboarding, ongoing reporting, and regular service reviews, serving as a single point of accountability.

Keep Your Drive, enabling customers to retain failed drives to maintain control of sensitive data and meet internal security and compliance requirements.

Global service coverage across more than 75 markets, delivering consistent, enterprise-grade support worldwide.

“According to recent IDC research, customers are placing as much, if not more, emphasis on services capabilities as on product features when evaluating vendors,” says Rob Brothers, VP, Services, IDC. “It’s not just the product, but the experience surrounding it that helps customers choose the right vendor for their needs. With the addition of Premier Support Plus, Lenovo is expanding its services portfolio, which is designed to enhance the overall Lenovo server experience.”


For customers with mission-critical environments where downtime is not an option, Lenovo also offers Committed Service Repair as an optional add-on. This enhanced service provides a 6-hour onsite repair commitment, delivering faster resolution for the most demanding operational needs.


Premier Support Plus combines predictive detection, preventative maintenance, and guided planning to keep infrastructure optimized and ready to scale. With designated account oversight from a Lenovo Service Engagement Manager, global coverage, and data retention controls through Keep Your Drive, customers gain consistent, transparent support they can trust. By shifting the burden of monitoring, maintenance, and escalation to Lenovo, IT teams can spend less time reacting to issues and more time driving strategic initiatives.


Premier Support Plus for Servers is part of Lenovo’s broader services portfolio, which includes Lenovo Lifecycle Services which are designed to help customers plan, deploy, manage, optimize and evolve IT infrastructure with confidence.


To learn more about Lenovo Premier Support Plus for Servers, visit: https://www.lenovo.com/us/en/services/support-services/premier-support-plus-for-infrastructure/.


About Lenovo


Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.


Disclaimers


Committed Service Repair (CSR) service availability may vary by product and location. Refer to the Lenovo Locator Tool to see if CSR is available in your location.


Response time is a target, not a guaranteed commitment. For more information, see the Lenovo Data Center Services Agreement.


LENOVO, THINKSYSTEM and THINKAGILE are trademarks of Lenovo. All other trademarks are the property of their respective owners. ©2026 Lenovo Group Limited. All rights reserved.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226453532/en/



Permalink

https://aetoswire.com/en/news/54433834


Contacts

 

Zeno Group for Lenovo SSG

Email: LenovoSSG@zenogroup.com

سامبا نوفا تطلق أسرع شريحة للذكاء الاصطناعي الوكيل في العالم وتتعاون مع إنتل وتجمع تمويل بأكثر من 350 مليون دولار


الشريحة الجديدة SN50 الجديدة تسجّل سرعة قصوى تفوق الشرائح المنافسة بـ 5 مرات [1]

سامبا نوفا تتيح تشغيل الذكاء الاصطناعي الوكيل بتكلفة أقل بـ 3 مرات مقارنة بوحدات معالجة الرسوميات (GPU) ما يخفض تكاليف الاستدلال ويعزز الهوامش [2]

ستكون شركة سوفت بنك كورب أول عميل يقوم بنشر منصة SN50 داخل مراكز بيانات الذكاء الاصطناعي من الجيل الجديد التابعة لها في اليابان

سامبا نوفا تتعاون مع إنتل وتجمع أكثر من 350 مليون دولار من التمويل

 


أطلقت سامبا نوفا (SambaNova) اليوم شرائح الذكاء الاصطناعي (SN50) التي توفّر سرعة قصوى تبلغ خمسة أضعاف سرعة الشرائح المنافسة، كما كشفت الشركة عن تعاونها مع شركة إنتل (Intel) لتقديم حلول استدلال عالية الأداء وفعالة من حيث التكلفة، كما أعلنت عن جمع أكثر من 350 مليون دولار من الاستثمارات الجديدة والقائمة.


وتعد (SN50) الشريحة الأكثر كفاءة للذكاء الاصطناعي الوكيل في العالم، إذ توفّر للمؤسسات تكلفة إجمالية للملكية أقل بنسبة 3 أضعاف من الشرائح المنافسة، مما يشكّل أساساً قوياً لتوسيع نطاق الاستدلال السريع وإدخال وكلاء الذكاء الاصطناعي الآليين إلى بيئات الإنتاج الكاملة. ومن المقرر بدء شحن الشرائح الجديدة للعملاء في وقت لاحق من هذا العام.


ولتسريع التوسع في إنتاج وتوزيع الشرائح الجديدة (SN50)، تعاونت شركة سامبا نوفا مع إنتل، كما حصلت على تمويل استراتيجي بقيمة 350 مليون دولار ضمن جولة تمويل (Series E) لتوسيع قدرات التصنيع والقدرات السحابية.


وقال رودريجو ليانج، الشريك المؤسس والرئيس التنفيذي لشركة سامبا نوفا: "لم يعد سباق الذكاء الاصطناعي يقتصر على بناء نماذج أكبر، بل أصبح السباق الحقيقي يتمحور حول تشغيل مراكز بيانات كاملة بوكلاء ذكاء اصطناعي تقدّم إجابات فورية ودون تأخير، وبتكلفة تحوّل الذكاء الاصطناعي من مجرد أداة للتجربة إلى عامل هامّ في تعزيز الأرباح عبر البيئات السحابية".


بدوره، قال كيفورك كيتشيشيان، النائب التنفيذي والمدير العام لمجموعة مراكز البيانات لدى إنتل: "يطالب العملاء اليوم بخيارات أكثر وطرق أكثر كفاءة لتوسيع نطاق الذكاء الاصطناعي. ويتيح الجمع بين ريادة إنتل في الحوسبة والشبكات والذاكرة وبين أنظمة سامبا نوفا المتكاملة ومنصة الاستدلال السحابية الخاصة بها خياراً قوياً للمؤسسات التي تبحث عن بدائل لوحدات معالجة الرسوميات (GPU) لنشر الذكاء الاصطناعي المتقدم على نطاق واسع".


توفّر شرائح (SN50) قدرة حوسبية أكبر بخمسة أضعاف وأربعة أضعاف عرض نطاق الشبكة مقارنة بالجيل السابق، كما يمكنها ربط ما يصل إلى 256 مسرّعاً عبر وصلات داخلية تتيح نقل البيانات بسرعات عالية تبلغ عدّة تيرابايت في الثانية، ما يقلّص زمن الاستجابة الأولي ويدعم التعامل مع دفعات بحجم أكبر من البيانات، مما يمكّن المؤسسات من تشغيل نماذج ذكاء اصطناعي أكبر وذات سياق أطول مع إنتاجية أعلى واستجابة أسرع، فضلاً عن الحفاظ على الأداء وتقليل التكلفة وزمن التأخير.


وقال لاندون داونز، الشريك المؤسس والشريك الإداري في كامبيوم كابيتال: "ينتقل الذكاء الاصطناعي من كونه مجرّد أداة برمجية ليصبح بمثابة بنية تحتية متكاملة، وقد تم تصميم شرائح الذكاء الاصطناعي (SN50) لتلبية متطلبات السرعة العالية والتكلفة المعقولة، وهذا العاملان سيحددان من ينجح في نشر الذكاء الاصطناعي الوكيل على نطاق واسع".


ويأتي هذا الإعلان بعد تسجيل سامبا نوفا أرقاماً قياسية في الحجوزات والإيرادات مع نهاية عام 2025، ما يعكس الطلب المتسارع على أنظمة الذكاء الاصطناعي الجاهزة للإنتاج عبر قطاعات الخدمات المالية والاتصالات والطاقة والذكاء الاصطناعي السيادي حول العالم.


 


مصممة لتعزيز إنتاجية الذكاء الاصطناعي الوكيل


تعتمد الشرائح (SN50) على بنية معمارية تعتمد على وحدات (RDU) القابلة لإعادة التهيئة، وتتمتع بما يلي:


تجارب ذكاء اصطناعي فورية: زمن استجابة منخفض للغاية يوفّر تفاعلاً فورياً مع تطبيقات المؤسسات من الجيل التالي مثل المساعدات الصوتية.

توسّع وتزامن غير مسبوقين: دعم آلاف الجلسات المتزامنة بأداء ثابت وعالٍ.

قدرة نموذجية متقدمة: ذاكرة ذات بنية ثلاثية المستويات تدعم نماذج بأكثر من 10 تريليونات مُعامل وسياقات تتجاوز 10 ملايين رمز، ما يتيح استدلالاً أعمق ومخرجات أكثر ثراءً.

كفاءة قصوى على نطاق واسع: رفع كفاءة استخدام التجهيزات والعتاد يخفض تكلفة كل رمز ويعزز الأداء والعائد على الاستثمار.

ذاكرة أذكى وكفاءة أعلى: ذاكرة مقيمة متعددة النماذج وآليات تخزين مؤقت وكيل لتحسين المعمارية الثلاثية وخفض تكاليف البنية التحتية.

 


وقال بيتر روتن، نائب رئيس الأبحاث للحوسبة عالية الأداء في شركة آي دي سي للأبحاث: "تُسبب شريحة SN50 RDU الجديدة من سامبا نوفا نقلة نوعية في اقتصاديات الرموز (Tokenomics) لعمليات الاستدلال بالذكاء الاصطناعي على نطاق واسع، حيث تغير تُغيّر سامبا نوفا قواعد اللعبة من خلال الجمع بين الأداء العالي ومعدلات الإنتاجية المرتفعة، مع شريحة لا تحتاج إلى طاقة إضافية وتعمل بتقنية التبريد عبر الهواء".


سوفت بنك ينشر شرائح SN50 ضمن مراكز بيانات الذكاء الاصطناعي في اليابان


سيكون بنك "سوفت بنك" أول عميل يعتمد شرائح الذكاء الاصطناعي (SN50) ضمن مراكز بيانات الذكاء الاصطناعي من الجيل التالي التابعة له في اليابان. وسيدعم هذا النشر خدمات الاستدلال السريعة للعملاء الراغبين بالخدمات الرقمية السيادية وللمؤسسات في منطقة آسيا والمحيط الهادئ، مع دعم النماذج مفتوحة المصدر والنماذج المتقدمة المملوكة على حدّ سواء، بما يلبي المتطلبات المتقدّمة من حيث زمن الاستجابة والإنتاجية.


وقال هيرونوبو تامبا، نائب الرئيس ورئيس قسم استراتيجية منصات البيانات في وحدة التقنية لدى سوفت بنك كورب: "تمكنا بفضل شرائح الذكاء الاصطناعي (SN50) من بناء نسيج متكامل لاستدلال الذكاء الاصطناعي في اليابان وقادراً على خدمة عملائنا وشركائنا بالسرعة والمرونة وتحقيق متطلبات السيادة الرقمية التي يتوقعونها من سوفت بنك. ومن خلال اعتمادشرائح (SN50) كمعيار أساسي، فقد أصبح لدينا القدرة على تقديم خدمات ذكاء اصطناعي عالمية المستوى وفق شروطنا الخاصة وبأداء يضاهي ما تقدمه وحدات معالجة الرسوميات، ولكن بكفاءة اقتصادية أعلى وقدرات تحكم أكبر".


ويعزّز إطلاق منصة (SN50) الشراكة الاستراتيجية القائمة بين سامبا نوفا وسوفت بنك كورب، حيث يستضيف البنك حالياً منصة "سامبا كلاود" لتقديم خدمات استدلال فائقة السرعة للمطورين في المنطقة. ومن خلال اعتماده على شرائح الذكاء الاصطناعي (SN50)، يكرّس سوفت بنك مكانة سامبا نوفا كمزوّد أساسي لعمليات الاستدلال ضمن مبادراتها للذكاء الاصطناعي السيادي، ولخدمات وكلاء الذكاء الاصطناعي على نطاق واسع في المستقبل.


سامبا نوفا وإنتل يتفقان على تعاون استراتيجي يمتدّ لعدة سنوات


أعلنت سامبا نوفا وإنتل عن خطط لتعاون استراتيجي يمتد لعدة سنوات، ويهدف إلى توفير حلول استدلال للذكاء الاصطناعي تمتاز بكونها عالية الأداء ومجدية من حيث التكلفة، سواء أمام الشركات المتخصصة في الذكاء الاصطناعي أو مزودي النماذج أو المؤسسات الكبرى أو الجهات الحكومية حول العالم. ويوفر هذا التعاون بديلاً قوياً للحلول التقليدية المعتمدة على وحدات معالجة الرسوميات، مع أداء مُحسَّن لأبرز النماذج مفتوحة المصدر، وإنتاجية مستقرة، وتكلفة إجمالية واضحة للملكية.


وبموجب هذا التعاون، تخطط إنتل لإجراء استثمار استراتيجي في سامبا نوفا لتسريع إطلاق سحابة ذكاء اصطناعي مدعومة بتقنيات إنتل. ومن المتوقع أن يشمل التعاون ثلاثة محاور رئيسية:


 


توسيع سحابة الذكاء الاصطناعي:

توسيع نطاق سحابة سامبا نوفا المتكاملة رأسياً، والمبنية على بنية تحتية تعتمد على معالجات إنتل زيون (Xeon)، والمُحسَّنة للتعامل مع النماذج اللغوية الكبيرة والنماذج متعددة الوسائط. وستوفر المنصة خدمات ذكاء اصطناعي بزمن استجابة منخفض وإنتاجية عالية، مدعومة بهياكل مرجعية ومخططات نشر وشراكات مع شركات تكامل الأنظمة ومزودي البرمجيات.

 


بنية تحتية متكاملة للذكاء الاصطناعي:

دمج أنظمة سامبا نوفا مع وحدات المعالجة المركزية والمسرّعات وتقنيات الشبكات من إنتل لتقديم حلول استدلال قابلة للتوسع وجاهزة لبيئات الإنتاج، تدعم مهام الاستدلال المنطقي، وتوليد الأكواد البرمجية، والتطبيقات متعددة الوسائط، وسير عمل وكلاء الذكاء الاصطناعي.

 


تسريع الدخول إلى السوق:

تنفيذ استراتيجيات بيع وتسويق مشتركة عبر قنوات إنتل العالمية في قطاع المؤسسات والحوسبة السحابية والشركاء، وذلك بهدف تسريع اعتماد حلول الذكاء الاصطناعي على مستوى العالم.

 


وتهدف الشركتان إلى الإسهام في رسم ملامح الجيل القادم من مراكز بيانات الذكاء الاصطناعي التي تعتمد على مكونات مختلفة، وذلك من خلال دمج معالجات إنتل زيون ووحدات إنتل معالجة الرسوميات وتقنيات الشبكات والتخزين مع أنظمة سامبا نوفا، بما يفتح آفاقاً سوقية تُقدَّر بمليارات الدولارات في مجال الاستدلال الخاص بالذكاء الاصطناعي.


جولة تمويل تتجاوز 350 مليون دولار بقيادة فيستا وكامبيوم


اختتمت سامبا نوفا جولة تمويل جديدة من الفئة E بقيمة تجاوزت 350 مليون دولار، وسط إقبال فاق التوقعات، بقيادة فيستا إيكويتي بارتنرز (Vista Equity Partners) وكامبيوم كابيتال (Cambium Capital)، وبمشاركة قوية من إنتل كابيتال. كما انضم إلى الجولة عدد من المستثمرين الجدد، من بينهم أسّام فينتشرز (Assam Ventures)، وباتري فينتشرز (Battery Ventures)، وشركة الخليج للتطوير وهي شركة مساهمة عامة محدودة (Gulf Development Public Company Limited)، وماي فيلد كابيتال (Mayfield Capital)، وسعودي فيرست داتا (Saudi First Data)، وسيليجمان فينتشرز (Seligman Ventures)، إضافة إلى حسابات تديرها (T. Rowe Price Associates, Inc.)،وشارك في الجولة أيضاً مستثمرون حاليون، من بينهم (A&E) و (8Square) و (Atlantic Bridge) و (BlackRock) و (GV) و (Nepenthe) و (Nuri Capital) و (Redline Capital).


وصرح الأستاذ شرف الحريري، رئيس مجلس إدارة شركة فيرست داتا (First Data)، بأن سامبا نوفا تشكل جزءاً أساسياً من استراتيجية فيرست داتا الاستثمارية الرامية إلى جلب تقنيات الذكاء الاصطناعي المتقدمة إلى المملكة العربية السعودية ومنطقة الشرق الأوسط. وأكد أن فيرست داتا تستثمر في منصات سامبا نوفا لتمكين قدرات الذكاء الاصطناعي ذات الأداء العالي والاستجابة السريعة والجاهزية للسيادة الرقمية، مع الاستفادة من الاستهلاك المنخفض للطاقة والقدرة على العمل بكفاءة ضمن بيئات مراكز البيانات الحالية المبردة بالهواء.


وضمن هذه الاستراتيجية، تدعم سامبا نوفا عمليات الاستدلال المتقدمة وخدمات الذكاء الاصطناعي القابلة للتوسع، مما يعزز قدرة فيرست داتا على تقديم بنية تحتية وحلول عالمية المستوى في مجال الذكاء الاصطناعي. كما أشار الحريري إلى أن هذا الاستثمار يعكس التزام فيرست داتا الأوسع وطويل الأمد بتنويع محفظتها التكنولوجية، وبناء قدرات ابتكارية مرنة، وتمكين الشركة من التكيف مع التوجهات التكنولوجية العالمية المتطورة، مع تقديم قيمة مستدامة للمنطقة.


ومع توسّع أعباء العمل القائمة على وكلاء الذكاء الاصطناعي، بدأت المؤسسات تدرك أن البنية التحتية المُحسّنة للتدريب تواجه صعوبة في تلبية المتطلبات من ناحية زمن الاستجابة في بيئات الإنتاج ومتطلبات الكلفة. وفي هذا السياق، قال مونتي ساروا، الشريك في فيستا: "إننا فخورون بالاستثمار في سامبا نوفا في مرحلة مفصلية من مسيرة نموها. فقد صُمِّمت شرائح الذكاء الاصطناعي (SN50) خصيصاً لدعم أنظمة الذكاء الاصطناعي الوكيل التي تنسّق بين نماذج متعددة وتعالج الطلبات في وقت شبه فوري، وبكفاءة أعلى من الأنظمة التقليدية المعتمدة على وحدات معالجة الرسوميات".


وسيتم توظيف عائدات التمويل في توسيع إنتاج شرائح الذكاء الاصطناعي الجديدة (SN50)، وتعزيز نطاق منصة سامبا كلاود، وتعميق تكامل الحلول مع برمجيات المؤسسات، بما يدعم الطلب المتزايد على حلول استدلال عالية الأداء وذات كلفة مجدية اقتصادياً.


صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260226805517/en



الرابط الثابت

https://aetoswire.com/ar/news/2702202653569


جهات الاتصال

عماد عبدو


Emad@memediapro.com


971522038872  

SambaNova Unveils Fastest Chip for Agentic AI, Collaborates with Intel, and Raises $350M+

  


New SN50 chip boasts a max speed of 5X faster than competitive chips [1]

Run agentic AI at a 3X lower cost than GPUs — slashing inference costs and maximizing margins [2]

SoftBank Corp. will be the first customer to deploy SN50 within its next‑generation AI data centers in Japan

SambaNova, Intel plan multi-year strategic collaboration to deliver cloud-scale AI inference to unlock multi-billion-dollar market opportunity

$350 million in strategic Series E financing to expand manufacturing and cloud capacity; new investors include Vista Equity Partners, Cambium Capital, First Data, Intel Capital, Battery Ventures, and accounts advised by T. Rowe Price Associates, Inc.

 


(BUSINESS WIRE)--SambaNova today introduced their SN50 AI chip, which boasts a max speed that’s 5X faster than competitive chips. The company also announced a planned collaboration with Intel to deliver high‑performance, cost‑efficient AI inference solutions, and more than $350M in investment from new and existing investors.


Positioned as the most efficient chip for agentic AI, the SN50 chip offers enterprises a 3X lower total cost of ownership — a powerful foundation to scale fast inference and bring autonomous AI agents into full production. The SN50 will be shipping to customers later this year.


To quickly scale and distribute SN50, SambaNova is collaborating with Intel, and has obtained $350 million in strategic Series E financing to expand manufacturing and cloud capacity.


“AI is no longer a contest to build the biggest model,” said Rodrigo Liang, co‑founder and CEO of SambaNova. “With the SN50 and our deep collaboration with Intel, the real race is about who can light up entire data centers with AI agents that answer instantly, never stall, and do it at a cost that turns AI from an experiment into the most profitable engine in the cloud.”


“Customers are asking for more choice and more efficient ways to scale AI,” said Kevork Kechichian, EVP, General Manager, Data Center Group, Intel. “By combining Intel’s leadership in compute, networking, and memory with SambaNova’s full-stack AI systems and inference cloud platform, we are delivering a compelling option for organizations looking for GPU alternatives to deploy advanced AI at scale.”


The SN50 delivers five times more compute per accelerator and four times more network bandwidth than the previous generation. It links up to 256 accelerators over a multi‑terabyte‑per‑second interconnect, cutting time‑to‑first‑token and supporting larger batch sizes. The result: Enterprises can deploy bigger, longer‑context AI models with higher throughput and responsiveness — while keeping performance high and costs and latency under control.


“AI is moving from a software story to an infrastructure story,” said Landon Downs, co-founder and managing partner at Cambium Capital. “SN50 is engineered for the real-world latency and economic requirements that will determine who successfully deploys agentic AI at scale.”


The news follows SambaNova’s record bookings and revenue as they closed out 2025, reflecting accelerating demand for production-ready AI systems across financial services, telecommunications, energy, and sovereign deployments worldwide.


Built for Agentic Production


Built on SambaNova’s Reconfigurable Data Unit (RDU) architecture, SN50 delivers:


Instant AI Experiences — Ultra‑low latency delivers real‑time responsiveness for next‑gen enterprise apps like voice assistants.

Unmatched Scale and Concurrency — Power thousands of simultaneous AI sessions with consistent high performance.

Breakthrough Model Capacity — Three‑tier memory architecture unlocks 10T+ parameter models and 10M+ context lengths for deeper reasoning and richer outputs.

Maximum Efficiency at Scale — Higher hardware utilization lowers cost‑per‑token, driving greater performance and ROI.

Smarter Memory, Smarter Efficiency — Resident multi‑model memory and agentic caching optimize the three‑tier architecture, cutting infrastructure costs for enterprise‑scale AI deployments.

“The new SambaNova SN50 RDU changes the tokenomics of AI inference at scale. By delivering both high performance and high throughput with a chip that uses existing power and is air cooled, SambaNova is changing the game,” says Peter Rutten, Research Vice-President Performance Intensive Computing at analyst firm IDC.


SoftBank Deploys SN50 within its AI Data Centers in Japan


SoftBank Corp. will be the first customer to deploy SN50 within its next‑generation AI data centers in Japan. The deployment will power low‑latency inference services for sovereign and enterprise customers across Asia‑Pacific, supporting both open‑source and proprietary frontier models with aggressive latency and throughput requirements.


“With SN50, we are building an AI inference fabric for Japan that can serve our customers and partners with the speed, resiliency and sovereignty they expect from SoftBank,” said Hironobu Tamba, Vice President and Head of the Data Platform Strategy Division of the Technology Unit at SoftBank Corp. “By standardizing on SN50, we gain the ability to deliver world‑class AI services on our own terms — with the performance of the best GPU clusters, but with far better economics and control.”


The SN50 deployment deepens SambaNova’s existing relationship with SoftBank Corp., which already hosts SambaCloud to provide ultra‑fast inference for developers in the region. By anchoring its newest clusters on SN50, SoftBank positions SambaNova as the inference backbone for its sovereign AI initiatives and future large‑scale agentic services.


SambaNova and Intel Plan Multi‑Year Collaboration


SambaNova and Intel have entered into a planned multi‑year strategic collaboration to deliver high‑performance, cost‑efficient AI inference solutions for AI‑native companies, model providers, enterprises, and government organizations around the world. The collaboration will give customers a powerful alternative to GPU‑centric solutions, offering optimized performance for leading open‑source models with predictable throughput and total cost of ownership.


As part of the collaboration, Intel plans to make a strategic investment in SambaNova to accelerate the rollout of an Intel‑powered AI cloud. The collaboration is expected to span three key areas:


AI Cloud Expansion — Scaling SambaNova’s vertically integrated AI cloud, built on Intel Xeon‑based infrastructure and optimized for large language and multimodal models. The platform will deliver low‑latency, high‑throughput AI services, supported by reference architectures, deployment blueprints, and partnerships with system integrators and software vendors.

Integrated AI Infrastructure — Combining SambaNova’s systems with Intel’s CPUs, accelerators, and networking technologies to power scalable, production‑ready inference for reasoning, code generation, multimodal applications, and agentic workflows.

Go‑to‑Market Execution — Joint co‑selling and co‑marketing through Intel’s global enterprise, cloud, and partner channels to accelerate adoption across the AI ecosystem.

Together, SambaNova and Intel aim to shape the next generation of heterogeneous AI data centers — integrating Intel Xeon processors, Intel GPUs, Intel networking and storage, and SambaNova systems — to unlock a multi‑billion‑dollar inference market opportunity.


Raises $350M+, led by Vista and Cambium


The oversubscribed Series E round was led by Vista Equity Partners and Cambium Capital, with strong participation from Intel Capital.


New investors joining the round include: Assam Ventures, Battery Ventures, First Data, Gulf Development Public Company Limited, Mayfield Capital, Saudi First Data, Seligman Ventures, and accounts advised by T. Rowe Price Associates, Inc. Existing investors participating include: A&E, 8Square, Atlantic Bridge, BlackRock, GV, Nepenthe, Nuri Capital, and Redline Capital.


Mr. Sharaf Al Hariri, Chairman of First Data, stated that SambaNova forms a core part of First Data’s investment strategy to bring advanced AI technologies to the Kingdom of Saudi Arabia and the wider Middle East region. He emphasized that First Data is investing in SambaNova’s platforms to enable high-performance, low-latency, and sovereign-ready AI capabilities, while benefiting from low power requirements and the ability to operate efficiently within existing air-cooled data center environments. Within this strategy, SambaNova supports advanced inference and scalable AI services, strengthening First Data’s ability to deliver world-class AI infrastructure and solutions. He further noted that this investment reflects First Data’s broader, long-term commitment to diversifying its technology portfolio, building resilient innovation capabilities, and positioning the company to adapt to evolving global technology trends while delivering sustainable value to the region.


As agentic workloads expand, enterprises are discovering that infrastructure optimized for training struggles to meet production latency and cost requirements: “We’re proud to be investing in SambaNova at such a pivotal time in the company’s growth,” said Monti Saroya, Partner at Vista Capital. “SN50 is engineered for agentic AI systems that orchestrate multiple models and process requests in near real-time more efficiently than traditional GPU-centric systems.”


Proceeds will be used to expand SN50 production, scale SambaCloud, and deepen enterprise software integrations.


About SambaNova


SambaNova is a leader in next‑generation AI infrastructure, providing a full stack platform that powers the fastest, most efficient AI inference for enterprises, NeoClouds, AI labs and service providers, and sovereign AI initiatives worldwide. Founded in 2017 and headquartered in San Jose, Calif., SambaNova delivers chips, systems and cloud services that enable customers to deploy state‑of‑the‑art models with superior performance, lower total cost of ownership and rapid time to value.


For more information, visit sambanova.ai or follow SambaNova on X and LinkedIn.


[1] SemiAnalysis InferenceX - Llama 3.3 70B max speed on Nvidia B200 at FP8 and 1K input/1k output - 184 tokens per second per user. Llama 3.3 70B max speed on SN50 at FP8 and 1K input/1k output - 895 tokens per second per user.


[2] SemiAnalysis InferenceX - Llama 3.3 70B throughput per chip on Nvidia B200 at FP8 and 1K input/1k output - across a range of configurations, total throughput per GPU versus total throughput per RDU moves from ~1X (at 33 tokens per second per user) to ~25X advantage for RDUs (at 184 tokens per second per user). 3X is derived as the average throughput advantage for SN50 across Llama 70B, GPT-OSS 120B and DeepSeek 671B, assuming a latency budget.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226805517/en/



Permalink

https://aetoswire.com/en/news/2702202653568


Contacts

Press Contact:

Emad Abdo

Emad@memediapro.com

+971522038872

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership


 

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods

Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods

Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year

Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion

(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.


“These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA has firmly established itself as the global leader in the BTK inhibitor class, distinguished by broad regulatory approvals, expanding geographic reach, strong physician adoption, and unmatched long-term efficacy and safety data in CLL. At the same time, we are securing new indications and expanded reimbursement for TEVIMBRA across key markets worldwide. With our late-stage, foundational hematology assets nearing commercialization and a robust solid tumor portfolio delivering encouraging data, we are well positioned to extend our leadership and drive the next phase of sustainable global growth.”


(Amounts in thousands of U.S. dollars full year GAAP amounts audited, all other amounts unaudited)



*  For an explanation of our use of non-GAAP financial measures refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.


Fourth Quarter and Full Year 2025 Financial Results


Product Revenue, which represents 99% of total revenue, totaled $1.5 billion and $5.3 billion for the fourth quarter and full year of 2025, representing growth of 32% and 40%, compared to the prior-year periods.


BRUKINSA: Global sales totaled $1.1 billion and $3.9 billion the fourth quarter and full year of 2025, representing growth of 38% and 49%, compared to the prior-year periods; U.S. sales of BRUKINSA totaled $845 million and $2.8 billion in the fourth quarter and full year of 2025, representing growth of 37% and 45%, compared to the prior-year periods.

TEVIMBRA (tislelizumab): Global sales totaled $182 million and $737 million, in the fourth quarter and full year of 2025, representing growth of 18% and 19%, compared to the prior-year periods.

Amgen in-licensed products: Global sales totaled $112 million and $486 million for the fourth quarter and full year of 2025, representing growth of 11% and 33%, compared to prior-year periods.

Gross Margin as a percentage of global product sales for the fourth quarter and full year of 2025 was 90.4% and 87.3%, compared to 85.6% and 84.3%, in the prior-year periods on a GAAP basis. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of global product sales increased to 90.7% and 87.8% for the fourth quarter and full year of 2025, compared to 87.4% and 85.5%, in the prior-year periods.


Operating Expenses


The following table summarizes operating expenses for the fourth quarter of 2025 and 2024:


Research and Development (R&D) Expenses increased for the fourth quarter and full year of 2025 compared to the prior-year periods on both a GAAP and adjusted basis. Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled nil and $0.7 million in the fourth quarter and full year of 2025, compared to $63 million and $114 million in the prior-year periods.


Selling, General and Administrative (SG&A) Expenses increased for the fourth quarter and full year of 2025 compared to the prior-year periods on both a GAAP and adjusted basis. SG&A expenses as a percentage of product sales were 38% and 39% for the fourth quarter and full year of 2025, compared to 45% and 48% in the prior-year periods.


Net Income/(Loss) and Basic/Diluted Earnings Per Share


GAAP net income for the fourth quarter and full year of 2025 was $67 million and $287 million, an increase of $218 million and $932 million, over the prior-year periods, primarily attributable to revenue growth and improved operating leverage. Included within GAAP net income for full year 2025 were $76 million of equity investment impairment charges, $25 million of non-recurring tax expenses and $20 million of timing related tax expenses in certain jurisdictions, which were primarily incurred in the fourth quarter.


For the fourth quarter of 2025, basic and diluted earnings per share were $0.05 and $0.04 per share and $0.60 and $0.58 per American Depositary Share (ADS), compared to basic loss of $0.11 per share and $1.43 per ADS in the prior-year period. For the full year of 2025, basic and diluted earnings per share were $0.20 and $0.19 per share and $2.63 and $2.53 per ADS, compared to basic loss of $0.47 per share and $6.12 per ADS in the prior-year period.


Free Cash Flow for the fourth quarter of 2025 was $380 million, representing an increase of $397 million over the prior-year period. For the full year of 2025, free cash flow was $942 million, representing an increase of $1.6 billion over the prior-year period.


For further details on BeOne’s 2025 Financial Statements, please see BeOne’s Annual Report on Form 10-K for fiscal year 2025 filed with the U.S. Securities and Exchange Commission.


Full Year 2026 Guidance


BeOne’s financial guidance is summarized below:


BeOne’s total revenue guidance for full year 2026 of $6.2 billion to $6.4 billion includes expectations for strong revenue growth driven by BRUKINSA’s U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and a full year of 2026 productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage.


The Company is providing the following additional guidance on items impacting net income and earnings per ADS:


Other income (expense): estimated range of $25 million to $50 million in expense, includes interest amortization from Royalty Pharma arrangement.

Income tax outlook: earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship.

Diluted ADS outstanding: the Company expects diluted ADSs outstanding of approximately 118 million.

Fourth Quarter Business Highlights


Core Marketed Products


BRUKINSA (zanubrutinib)


Presented 6-year landmark results from the Phase 3 SEQUOIA trial and long-term results from the Phase 3 ALPINE trial at the American Society of Hematology (ASH) Annual Meeting, confirming sustained benefit for the treatment of adult patients with treatment-naïve (TN) and relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), respectively.

Sonrotoclax (BCL2 inhibitor)


Received first global approvals in China for the treatment of adult patients with:

R/R mantle cell lymphoma (MCL) who have received at least two systemic therapies, including a Bruton tyrosine kinase (BTK) inhibitor;

and R/R CLL/SLL who have previously received at least one systemic therapy, including a BTK inhibitor.

Granted U.S. Food and Drug Administration (FDA) priority review for the treatment of adult patients with R/R MCL.

Submitted Marketing Authorization Application in the European Union for the treatment of adult patients with R/R MCL.

Enrolled first subject in Phase 3 trial in combination with BRUKINSA as a fixed-duration regimen versus acalabrutinib plus venetoclax for the treatment of adult patients with TN CLL.

TEVIMBRA (tislelizumab)


Presented full results in partnership with Jazz Pharmaceuticals and Zymeworks from the HERIZON-GEA-01 trial in combination with ZIIHERA (zanidatamab) and chemotherapy, demonstrating statistically significant and clinically meaningful improvement in overall survival versus trastuzumab plus chemotherapy for the first-line treatment of adult patients with HER2-positive gastroesophageal adenocarcinoma (GEA).

Select Clinical-Stage Programs


Hematology


BGB-16673 (BTK chimeric degradation activation compound (CDAC)): Presented results at ASH from the Phase 1 CaDAnCe-101 trial for the treatment of adult patients with R/R CLL.

Breast and Gynecologic Cancers


BG-75202 (KAT6A/B inhibitor): Initiated first in human study.

BG-75908 (CDK2 CDAC): Initiated first in human study.

Lung Cancer


BG-C0902 (EGFRxMETxMET antibody-drug conjugate): Initiated first in human study.

Gastrointestinal Cancers


BGB-B2033 (GPC3x41BB bispecific antibody): Granted FDA Fast Track Designation for the treatment of adult patients with hepatocellular carcinoma who experience disease progression on or after post-systemic therapy.

Anticipated R&D Milestones


The Company’s earnings conference call for the fourth quarter and full year 2025 will be broadcast via webcast at 8:00 a.m. ET on Thursday, February 26, 2026, and will be accessible through the Investors section of BeOne’s website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.


About BeOne


BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.


To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: potential commercialization of BeOne’s late-stage hematology assets; BeOne’s next phase of global growth; BeOne’s future revenue, gross margin percentage, operating expenses, operating income, other income or expense, income tax and diluted ADS outstanding; BeOne’s expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical developments and data readouts; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226660598/en/



Permalink

https://www.aetoswire.com/en/news/54433496


Contacts

 Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com


 

Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years

  

  • Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1
  • These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1
  • Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5
  • Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami and build on previous data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one with a LTE study.1,6,7


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226796734/en/


“Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, long-term disease control is critical for patients. These data show that Nemluvio can make a meaningful difference to people’s lives by improving itch, skin lesions and quality of life up to three years, with a well-tolerated safety profile.”


DOCTOR SHAWN KWATRA, M.D.

LEAD INVESTIGATOR OF OLYMPIA PROGRAM

JOSEPH W. BURNETT ENDOWED PROFESSOR AND CHAIRMAN OF DERMATOLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE


Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life

The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and included 508 patients from the phase II trial and the OLYMPIA 1 and 2 phase III trials.1 At Week 148, in evaluable patients, the interim analysis showed that Nemluvio maintained long-term disease control with a consistent safety profile:

Over 70% of patients achieved clear or almost clear skin lesions based on Investigator’s Global Assessment score, and over 85% achieved more than 75% of healed lesions based on prurigo activity score.1

Over 85% of patients achieved a clinically meaningful itch improvement, and about three-quarters attained an itch-free or nearly itch-free state.1

About 90% of patients achieved a clinically meaningful improvement in quality of life, and >50% achieved a Dermatology Life Quality Index score of zero or one, meaning no effect of the disease on quality of life.1

The long-term safety profile of Nemluvio remained consistent with previous findings and aligned with previously established safety data for prurigo nodularis.1

 

“We recognize that prurigo nodularis is a chronic, debilitating condition that patients often struggle with for many years. Our goal has always been to generate robust, long-term evidence on how to ease such disease burden for patients suffering from prurigo nodularis, drawing on data from the largest completed pivotal clinical program and now the longest extension study reported in this disease to date.”



BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.

GLOBAL HEAD OF R&D

GALDERMA


Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2-5 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis.2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the U.S. and EU.4,5


Media can find more information and resources on prurigo nodularis in this toolkit.


About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.8,9


Nemluvio was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, and patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.4 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the EU, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing.


About prurigo nodularis

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.10-12 It is estimated to affect between 7-111 people per 100,000 in the EU depending on the country and up to 181,000 people in the U.S.13-16 The majority of patients report that the persistent itch negatively impacts their quality of life.17 Furthermore, the intense itch associated with prurigo nodularis results in significant sleep disturbance and further contributes to reduced quality of life.18,19


About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.


References


Kwatra SG, et al. Nemolizumab long-term safety and efficacy up to 148 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis. Presented at Winter Clinical Miami; February 27- March 1, 2026; Florida, U.S.

Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013.

Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039-2048. doi: 10.1007/s13555-022-00782-2.

Nemluvio® U.S. Prescribing Information. Available online. Accessed February 2026.

Nemluvio® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed February 2026.

ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed February 2026.

ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed February 2026.

Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed February 2026.

Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed February 2026.

Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042.

Huang AH, et al. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183.

Pereira MP, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570.

Ryczek A, and Reich A. Prevalence of Prurigo Nodularis in Poland. Acta Derm Venereol. 2020;100:adv00155. doi: 10.2340/00015555-3518.

Ständer S, et al. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Acta Derm Venereol. 2020;100(18):1-6. doi: 10.2340/00015555-3655.

Kwatra SG, et al. Prevalence of prurigo nodularis in the United States. JAAD Int. 2024;18:134-136. doi: 10.1016/j.jdin.2023.12.013.

Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009.

Todberg T, et al. Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study. Acta Derm Venereol. 2020;100(8):adv00119. doi: 10.2340/00015555-3471.

Kwatra SG. Breaking the Itch–Scratch Cycle in Prurigo Nodularis. N Engl J Med. 2020;382(8):757-758. doi: 10.1056/NEJMe1916733.

Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277-1284. doi: 10.1111/ced.14722.

 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226796734/en/



Permalink

https://www.aetoswire.com/en/news/2702202653573


Contacts

For further information:


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50


Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62


Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87


Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12


Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43


 

Friday, February 27, 2026

أورينت فاينانس تؤكد أهمية الاستراتيجية المنضبطة في ظل تقلبات السوق المتزايدة


في ظل استمرار تقلبات الأسواق المالية العالمية نتيجةً لعدم اليقين الاقتصادي الكلي، وتغير السياسات النقدية، والضغوط التضخمية، والتطورات الجيوسياسية، تُشدد أورينت فاينانس (Orient Finance) على أهمية التوجيه المنظم، والاستراتيجية المنضبطة، واتخاذ القرارات المدروسة.


تتمتع أورينت فاينانس، التي تعمل منذ عام 1994 وتخضع لرقابة هيئة سوق المال في الإمارات العربية المتحدة، بخبرة واسعة في التعامل مع دورات السوق المتعددة على مدى عقود. وتشير الشركة إلى أن فترات التقلبات المتزايدة، والتي غالباً ما تُعتبر عدم استقرار، هي سمة متأصلة في الأنظمة المالية العالمية.


يمكن أن تخلق تقلبات السوق فرصاً وتحديات على حد سواء. ومع ذلك، يمكن أن تُفاقم التقلبات أيضاً التحيزات السلوكية، واتخاذ القرارات العاطفية، ونشاط التداول كرد فعل - وهي عوامل تؤثر بشكل متكرر على نتائج المستثمرين. غالباً ما تُسهم تحركات الأسعار المفاجئة، والتحولات السريعة في معنويات السوق، وعدم اليقين المحيط بالمؤشرات الاقتصادية في ضغوط اتخاذ القرارات قصيرة الأجل.


وقد صرح سراج أسد خان، العضو المنتدب لشركة أورينت فاينانس، قائلاً:


"يُعدّ التقلب عنصراً طبيعياً في الأسواق المالية، لا سيما خلال فترات التحول الاقتصادي وعدم اليقين العالمي. ومن خلال خبرتنا الممتدة لعقود في تطور السوق، لاحظنا أن تحقيق نتائج مستدامة غالباً ما يكون مدفوعاً بالتحليل الدقيق، وإدارة المخاطر المنظمة، والرؤية الاستراتيجية. ويستفيد المستثمرون عندما تُبنى قراراتهم على التخطيط المسبق والإطار العام بدلاً من ردود الفعل القصيرة الأجل."


وتؤكد أورينت فاينانس أن التعامل مع الظروف المتقلبة يتطلب أكثر من مجرد التحليل الفني. فالنهج المتوازن الذي يجمع بين مبادئ إدارة المخاطر، واستراتيجيات الحفاظ على رأس المال، والانضباط السلوكي، يبقى أمراً بالغ الأهمية.


تؤكد الشركة أن التقلبات السوقية غالبًا ما تكشف الفرق بين القرارات المضاربية والاستراتيجيات المدروسة. إذ يمكن أن تكشف اضطرابات السوق عن نقاط ضعف في ضوابط المخاطر، وحجم المراكز، والقدرة على التكيف العاطفي، مما يعزز أهمية التثقيف والاستعداد.


ومن خلال مواردها التعليمية، ورؤاها التحليلية، ومبادراتها التفاعلية المدروسة، تواصل أورينت فاينانس دعم عملائها في فهم دورات السوق، وتفسير الظروف المتغيرة، وإدارة المخاطر بفعالية أكبر.


كما تشير الشركة إلى أن التقلبات السوقية، رغم ارتباطها غالبًا بعدم اليقين، قد توفر فرصًا للمستثمرين المجهزين بالمعرفة والاستراتيجية المناسبتين. ومع ذلك، يُفضل التعامل مع هذه الفرص بتقييم مدروس بدلًا من الاستجابة الاندفاعية.


وتؤكد أورينت فاينانس أن وعي المستثمرين ومشاركتهم المنضبطة يظلان أساسيين خلال فترات تقلبات السوق، لا سيما مع تكيف الأنظمة المالية العالمية مع الظروف الاقتصادية المتغيرة.


من خلال التركيز على التعليم والتوجيه المنظم واتخاذ القرارات التحليلية، تسعى أورينت فاينانس إلى تعزيز المشاركة المسؤولة في الأسواق المالية ومساعدة المستثمرين على التعامل مع التعقيدات بثقة ووضوح أكبر.


 


للمزيد من المعلومات حول منصة أورينت فاينانس وبرامجها، تفضل بزيارة الموقع الإلكتروني:


https://orientfinance.com/



الرابط الثابت

https://aetoswire.com/ar/news/OF2722026A


جهات الاتصال

أنيرود مينون


anirudh@orientfinance.com  

Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle


 MUNICH -

Excellent momentum and record operating profit


Total business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments

Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever

Shareholders’ core net income advances 10.9 percent to 11.1 billion euros

Core earnings per share (EPS) grow 12.5 percent and reach 28.61 euros

Core return on equity (RoE) reaches an excellent level of 18.1 percent

Solvency II ratio2 increases 10 percentage points to 218 percent supported by excellent capital generation

4Q 2025


Diversified growth and double-digit increase in shareholders’ core net income

Total business volume rises 6.5 1 percent with contributions from all segments

Operating profit increases 3.0 percent to 4.3 billion euros, driven by excellent contribution from the Property-Casualty segment

Shareholders’ core net income advances 12.2 percent and reaches 2.7 billion euros

Outlook & other


For 2026, Allianz targets an operating profit of 17.4 billion euros, plus or minus 1 billion euros3

Management to propose a dividend per share of 17.10 euros, an increase of 11.0 percent from 2024

Allianz has announced a new share buy-back program of up to 2.5 billion euros on February 25, 2026

CEO comment


“Allianz’s record results for 2025 demonstrate – again – our ability to deliver reliably, including in rapidly shifting and increasingly divisive environments. The strength of our performance and fundamentals goes well beyond our financial discipline and operational resilience. Our success is also powered by our leading brand strength, record customer loyalty, and highly motivated employees.


Customers expect protection and peace of mind at a price that they can afford, which is why our ability to offer superior value is so vital to the continued growth of our customer base. To mitigate deepening polarization in the world, it remains our strategic priority – as well as our societal responsibility – to ensure that people can access the freedom and security that our products and services provide.”


- Oliver Bäte, Chief Executive Officer of Allianz SE


FINANCIAL HIGHLIGHTS


Allianz Group: An excellent start to our Capital Markets Day delivery


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

Total business volume (€ bn)4


 

45.7


 

6.5


%


 

186.9


 

8.1


%


Operating profit (€ mn)


 

4,297


 


 

3.0


%


 

17,374


 


 

8.4


%


Shareholders’ core net income (€ mn)


 

2,731


 


 

12.2


%


 

11,113


 


 

10.9


%


Core return on equity (%)


 

18.1


 


 

1.2%-p


 

Solvency II ratio (%)


 

218


 


 

10%-p


 

CFO comment


“We had an excellent start into our new strategic cycle. Our performance highlights the strength and resilience of Allianz’s business model.


Allianz’s record results for 2025 are characterized by very good growth across our segments and excellent profitability, while we further enhanced our financial strength. This demonstrates our ability to create sustainable value for our customers and shareholders alike.


As we pursue our 2026 target of an operating profit of 17.4 billion euros, plus or minus 1 billion euros, we continue the focused execution of our strategic Capital Markets Day priorities to deliver on our 2025 – 2027 plan.”


- Claire-Marie Coste-Lepoutre, Chief Financial Officer of Allianz SE


Allianz’s 12M 2025 results were excellent. Allianz sustained its momentum across all three segments and achieved a record operating profit.


Our total business volume expanded to 186.9 billion euros (12M 2024: 179.8 billion euros). Internal growth, which excludes the effects of foreign-currency translation as well as acquisitions and divestments, was strong at 8.1 percent, supported by growth across all segments.


Operating profit reached a record level of 17.4 (16.0) billion euros, an increase of 8.4 percent. The Property-Casualty business was the main growth driver and all business segments exceeded their full-year outlook midpoints.


Shareholders’ core net income rose by 10.9 percent to 11.1 (10.0) billion euros. Adjusted for a one-off tax provision related to the sale of our stake in our Indian Joint Ventures in 1Q 2025 and the divestment gain on the UniCredit Joint Venture in 2Q 2025, shareholders’ core net income was up by 9.3 percent.


Core earnings per share (EPS)5 amounted to 28.61 (25.42) euros, an increase of 12.5 percent. Adjusted for the above-mentioned one-off tax provision and divestment gain, core earnings per share rose 10.8 percent.


Allianz has delivered an excellent core return on equity (RoE)5 of 18.1 percent in 12M 2025 (12M 2024: 16.9 percent). Adjusted for the effects of the one-off tax provision and divestment gain, the core return on equity was 17.8 percent.


This performance was achieved while Allianz further strengthened its capitalization. The Solvency II ratio was 218 percent, an increase of 10 percentage points compared to full-year 2024 (209 percent) and 3Q 2025 (209 percent). This development was supported by excellent operating capital generation of 25 percentage points after tax/before dividend.


In 4Q 2025, Allianz delivered a strong performance, characterized by good growth across our three segments and excellent profitability.


Our total business volume amounted to 45.7 billion euros (4Q 2024: 45.9 billion euros). Internal growth was good at 6.5 percent and all segments contributed.


Operating profit rose 3.0 percent to 4.3 (4.2) billion euros, reaching 27 percent of our full-year outlook midpoint. The increase was mainly driven by excellent operating profit growth in our Property-Casualty business.


Shareholders’ core net income advanced 12.2 percent to 2.7 (2.4) billion euros. A higher operating profit and an improved non-operating result contributed.


Outlook


In 2026, Allianz targets an operating profit of 17.4 billion euros, plus or minus 1 billion euros.


Other


The Board of Management proposes a dividend per share of 17.10 euros (2024: 15.40 euros) for 2025, an increase of 11.0 percent from 2024.


On February 25, 2026, Allianz has announced a new share buy-back program of up to 2.5 billion euros.


Property-Casualty insurance: Excellent delivery across all dimensions


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

Total business volume (€ bn)4


 

19.9


 

6.7


%


 

86.7


 

8.2


%


Operating profit (€ mn)


 

2,134


 


 

9.6


%


 

8,992


 


 

13.9


%


Combined ratio (%)


 

93.6


 


 

-1.1%-p


 

92.2


 


 

-1.3%-p


 

Loss ratio (%)


 

69.8


 


 

-0.9%-p


 

68.3


 


 

-1.0%-p


 

Expense ratio (%)


 

23.8


 


 

-0.2%-p


 

23.9


 


 

-0.3%-p


 

Core messages Property-Casualty insurance 12M 2025


Very good internal growth across retail and commercial

Record operating profit, well exceeding the full-year outlook midpoint

Excellent combined ratio supported by underwriting actions

In the 12M 2025 period, total business volume rose to 86.7 billion euros (12M 2024: 82.9 billion euros). Internal growth was very good at 8.2 percent.


Operating profit was excellent at 9.0 (7.9) billion euros, well exceeding our full-year outlook midpoint of 8.0 billion euros. Operating profit growth of 13.9 percent was almost exclusively driven by a higher operating insurance service result.


The combined ratio was at an excellent level of 92.2 percent (93.4 percent), with improvements in the loss ratio and the expense ratio. The loss ratio reached 68.3 percent, an improvement of 1.0 percentage point compared to prior year (69.3 percent). Lower natural catastrophe losses and underlying improvements from underwriting actions overcompensated a conservative run-off ratio. The expense ratio improved by 0.3 percentage points to 23.9 percent (24.2 percent), reflecting a successful ongoing productivity focus.


The retail6 business delivered excellent internal growth of 9 percent while our commercial7 business grew by 7 percent.


Profitability in both retail and commercial was strong. The retail combined ratio improved 1.8 percentage points to 92.4 percent (94.1 percent), while in commercial the combined ratio reached an excellent level of 91.7 percent (92.2 percent), an improvement of 0.5 percentage points.


Core messages Property-Casualty insurance 4Q 2025


Strong internal growth of 6.7 percent

Excellent operating profit of 2.1 billion euros, up 10 percent

Very good combined ratio, supported by a better loss ratio and expense ratio

In 4Q 2025, total business volume reached 19.9 billion euros (4Q 2024: 19.5 billion euros), a strong internal growth of 6.7 percent.


The operating profit grew to 2.1 (1.9) billion euros, an increase of 9.6 percent, reaching 27 percent of our full-year outlook midpoint. A stronger operating insurance service result was the main driver.


The combined ratio improved to a very good level of 93.6 percent (94.7 percent). The loss ratio was 69.8 percent (70.7 percent), an improvement of 0.9 percentage points. The expense ratio improved by 0.2 percentage points to 23.8 percent (24.1 percent).


Our retail business delivered excellent internal growth of 9 percent and the combined ratio reached 94.5 percent (94.0 percent).


The commercial business achieved an internal growth of 3 percent, carefully managing the market environment, while the combined ratio improved by 4.0 percentage points to a strong level of 92.6 percent (96.6 percent).


Life/Health insurance: Consistently good results


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

PVNBP (€ mn)


 

21,163


 

-0.2


%


 

84,682


 

3.5


%


New business margin (%)


 

5.8


 


 

0.3%-p


 

5.7


 


 

-0.0%-p


 

Value of new business (€ mn)


 

1,217


 


 

5.3


%


 

4,829


 


 

2.9


%


Operating profit (€ mn)


 


1,364


 


 


-4.2


%


 


5,601


 


 


1.7


%


Contractual Service Margin (€ bn, eop)


 


55.7


 


 


1.4%8


 

 


55.7


 


 


5.2%9


 

Core messages Life/Health insurance 12M 2025


Good PVNBP growth of 3.5 percent from exceptionally high prior year level

Very good normalized CSM growth of 5.2 percent

Operating profit above full-year outlook midpoint

In 12M 2025, PVNBP, the present value of new business premiums, reached 84.7 billion euros (12M 2024: 81.8 billion euros), an increase of 3.5 percent from an exceptionally high prior year level or 7.5 percent higher adjusted for foreign currency translation effects and scope changes10. Growth was spread across most regions. The share of new business premiums generated in our preferred lines was 91 percent (93 percent).


The new business margin remained strong at 5.7 percent (5.7 percent) and the value of new business rose to 4.8 (4.7) billion euros, an increase of 5.8 percent adjusted for foreign currency translation effects and scope changes10.


Operating profit grew to 5.6 (5.5) billion euros, an increase of 1.7 percent, and exceeding our full-year outlook midpoint.


The Contractual Service Margin (CSM) remained broadly stable at 55.7 billion euros compared to 55.6 billion euros11 at the end of 2024. Very good normalized CSM growth of 5.2 percent was largely offset by foreign currency translation effects and non-economic movements.


Core messages Life/Health insurance 4Q 2025


New business margin strong at 5.8 percent

Value of new business increases 12 percent adjusted for foreign currency translation effects and scope changes

Operating profit good at 1.4 billion euros

In 4Q 2025, PVNBP, the present value of new business premiums, amounted to 21.2 billion euros (4Q 2024: 21.2 billion euros), an increase of 7.8 percent adjusted for foreign currency translation effects and scope changes10. The share of new business premiums generated in our preferred lines was 90 percent (92 percent).


The new business margin (NBM) of 5.8 percent (5.5 percent) was strong and above our ambition of at least 5 percent. The value of new business (VNB) increased by 5.3 percent to 1.2 (1.2) billion euros or 11.7 percent adjusted for foreign currency translation effects and scope changes10.


Operating profit reached a good level of 1.4 (1.4) billion euros, amounting to 25 percent of our full-year outlook midpoint.


Contractual Service Margin (CSM) increased to 55.7 billion euros (3Q 2025: 55.5 billion euros). Normalized CSM growth of 1.4 percent was very good and overcompensated non-economic movements.


Asset Management: Excellent third-party net inflows


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

Operating revenues (€ bn)12


 

2.3


 

5.8


%


 

8.5


 

5.9


%


Operating profit (€ mn)


 

928


 


 

-1.5


%


 

3,345


 


 

3.3


%


Cost-income ratio (%)


 

60.0


 


 

-0.0%-p


 

60.7


 


 

-0.4%-p


 

Third-party net flows (€ bn)


 

45.5


 


 

173.2


%


 

139.3


 


 

64.2


%


Third-party assets under management (€ bn)


 

1,990


 


 

3.6


%


Average third-party assets under management (€ bn)


 


1,978


 


 


4.8


%


 


1,914


 


 


5.8


%


Core messages Asset Management 12M 2025


Operating profit increases 3 percent to 3.3 billion euros

Cost-income ratio improves to 60.7 percent, ahead of full-year ambition of around 61 percent

Excellent third-party net inflows of 139 billion euros

In 12M 2025, operating revenues increased to 8.5 billion euros (12M 2024: 8.3 billion euros), an internal growth of 5.9 percent. Growth was driven by higher AuM-driven revenues, which advanced by 8.3 percent adjusted for foreign currency translation effects. This was supported by higher average third-party AuM.


Operating profit rose to 3.3 (3.2) billion euros, up 3.3 percent, or 6.9 percent adjusted for foreign currency translation effects. The cost-income ratio (CIR) improved to a very good level of 60.7 percent (61.1 percent), ahead of our full-year ambition of around 61 percent. This development reflects strong underlying revenue momentum and management actions.


Third-party assets under management amounted to 1.990 (1.920) trillion euros as of December 31, 2025, reaching an all-time high. Excellent net inflows of 139 billion euros and positive market effects of 94 billion euros were partly offset by negative foreign currency translation effects of 170 billion euros. Average third-party assets under management amounted to 1.914 trillion euros, 5.8 percent above the 2024 average.


Core messages Asset Management 4Q 2025


Assets under management (AuM)-driven revenues grow by 10 percent (F/X adjusted)

Operating profit at 928 million euros, reaching 28 percent of our full-year outlook midpoint

Strong third-party net inflows of 45 billion euros

In 4Q 2025, operating revenues reached 2.3 billion euros (4Q 2024: 2.4 billion euros), an internal growth of 5.8 percent. This was due to higher AuM-driven revenues, which increased by 10.5 percent adjusted for foreign currency translation effects.


Operating profit amounted to 928 (941) million euros, an increase of 5.3 percent adjusted for foreign currency translation effects. The cost-income ratio (CIR) was stable at an excellent level of 60.0 percent (60.0 percent).


Third-party assets under management of 1.990 trillion euros as of December 31, 2025 increased by 3.2 percent compared to 3Q 2025 (4Q 2024: 1.920 trillion euros; 3Q 2025: 1.928 trillion euros). Strong net inflows of 45 billion euros and market effects of 20 billion euros were the drivers. Average third-party assets under management increased 4.8 percent compared to 4Q 2024 and reached 1.978 trillion euros.


FOOTNOTES


_____________________________________

1


Internal growth; total growth 4.0 percent in 12M 2025 and -0.5 percent in 4Q 2025.


2


Solvency II ratio / Solvency II capitalization ratio: ratio that expresses the capital adequacy of a company by comparing own funds to SCR. This applies to all information related to the Solvency II ratio in this document.


3


As always, natural catastrophes and adverse developments in the capital markets, as well as factors stated in our cautionary note regarding forward-looking statements may severely affect the operating profit and/or net income of our operations and the results of the Allianz Group.


4


Change refers to internal growth.


5


Core EPS and core RoE calculation based on shareholders‘ core net income.


6


Retail including SME and Fleet. This applies to all information related to retail in this document.


7


Commercial including large Corporate, MidCorp, credit insurance, internal and 3rd party R/I. This applies to all information related to commercial in this document.


8


Normalized CSM growth fourth quarter 2025.


9


Normalized CSM growth 2025, percentage calculated including the scope changes in the base value in the first quarter 2025 and including UniCredit Allianz Vita S.p.A. until the sale in the second quarter 2025.


10


Sale of our stake in UniCredit JV and transfer of our German accident insurance with premium refund (APR) and the Austrian health businesses from the P/C segment to the L/H segment.


11


Figure includes gross CSM of EUR 0.8 bn as of December 31, 2024 for UniCredit Allianz Vita S.p.A., which was classified as held for sale in the third quarter of 2024.


12


Internal growth.


   

4Q & 12M 2025 RESULTS TABLE


Allianz Group - key figures 4th quarter and fiscal year 2025


 

 


 

 


 

 


 

 


 


 

 


 

 


 

 


 


 


 


 


 

 


 


4Q 2025


 


4Q 2024


 


Delta


 


 


12M 2025


 


12M 2024


 


Delta


 


Total business volume


 

€ bn


 


45.7


 


45.9


 


-0.5%


 


 


186.9


 


179.8


 


4.0%


 


- Property-Casualty


 


 


 

€ bn


 


19.9


 


19.5


 


1.7%


 


 


86.7


 


82.9


 


4.7%


 


- Life/Health


 


 


 

€ bn


 


23.6


 


24.3


 


-2.6%


 


 


92.3


 


89.3


 


3.4%


 


- Asset Management


 


 

€ bn


 


2.3


 


2.4


 


-1.5%


 


 


8.5


 


8.3


 


2.2%


 


- Consolidation


 


 

€ bn


 


-0.1


 


-0.3


 


-42.7%


 


 


-0.6


 


-0.7


 


-16.5%


 


Operating profit / loss


 

 


 

€ mn


 


4,297


 


4,174


 


3.0%


 


 


17,374


 


16,023


 


8.4%


 


- Property-Casualty


 


 


 

€ mn


 


2,134


 


1,948


 


9.6%


 


 


8,992


 


7,898


 


13.9%


 


- Life/Health


 


 


 

€ mn


 


1,364


 


1,424


 


-4.2%


 


 


5,601


 


5,505


 


1.7%


 


- Asset Management


 


 


 

€ mn


 


928


 


941


 


-1.5%


 


 


3,345


 


3,239


 


3.3%


 


- Corporate and Other


 


 


 

€ mn


 


-129


 


-140


 


-7.7%


 


 


-565


 


-615


 


-8.2%


 


- Consolidation


 

€ mn


 


0


 


1


 


-69.6%


 


 


1


 


-4


 


n.m.


 


Net income


 


 


 

€ mn


 


2,821


 


2,636


 


7.0%


 


 


11,430


 


10,540


 


8.4%


 


- attributable to non-controlling interests


 

€ mn


 


157


 


163


 


-3.9%


 


 


655


 


609


 


7.7%


 


- attributable to shareholders


 


 

€ mn


 


2,664


 


2,472


 


7.7%


 


 


10,775


 


9,931


 


8.5%


 


Shareholders’ core net income1


 

€ mn


 


2,731


 


2,434


 


12.2%


 


 


11,113


 


10,017


 


10.9%


 


Core earnings per share2


 


 


7.17


 


6.31


 


13.7%


 


 


28.61


 


25.42


 


12.5%


 


Dividend per share


 


 



 



 



 


 


17.10


3


15.40


 


11.0%


 


Additional KPIs


 


 

 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


- Group


 


Core return on equity4


 

%


 



 



 



 


 


18.1%


 


16.9%


 


1.2%


-p


- Property-Casualty


 


Combined ratio


 

%


 


93.6%


 


94.7%


 


-1.1%


-p


 


92.2%


 


93.4%


 


-1.3%


-p


- Life/Health


 


New business margin


 

%


 


5.8%


 


5.5%


 


0.3%


-p


5.7%


 


5.7%


 


-0.0%


-p


- Asset Management


 


Cost-income ratio


 

%


 


60.0%


 


60.0%


 


-0.0%


-p


 


60.7%


 


61.1%


 


-0.4%


-p


 


 


 


 

 


 


 


 


 


 


 


 


 


12/31/2025


 


12/31/2024


 


Delta


 


Shareholders' equity5


 


 


 

€ bn


 


 


 


 


 


 


 


 


62.7


 


60.3


 


4.0%


 


Contractual service margin (net)6


 

€ bn


 


 


 


 


 


 


 


 


35.4


 


34.5


 


2.4%


 


Solvency II capitalization ratio7


 

%


 


 


 


 


 


 


 


 


218%


 


209%


 


10%


-p


Third-party assets under management


 


 

€ bn


 


 


 


 


 


 


 


 


1,990


 


1,920


 


3.6%


 


 

 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 

Please note: The figures are presented in millions of Euros, unless otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.


1_


Presents the portion of shareholders’ net income before non-operating market movements and before amortization of intangible assets from business combinations (including any related income tax effects).


2_


Calculated by dividing the respective period’s shareholders' core net income, adjusted for net financial charges related to undated subordinated bonds classified as shareholders' equity, by the weighted average number of shares outstanding (basic core EPS).


3_


Proposal.


4_


Represents the ratio of shareholders’ core net income to the average shareholders’ equity at the beginning and at the end of the year. Shareholders’ core net income is adjusted for net financial charges related to undated subordinated bonds classified as shareholders’ equity. From the average shareholders’ equity, undated subordinated bonds classified as shareholders’ equity, unrealized gains and losses from insurance contracts and other unrealized gains and losses are excluded.


5_


Excluding non-controlling interests.


6_


Includes net CSM of EUR 0.3bn as of 31 December 2024 for UniCredit Allianz Vita S.p.A., which was classified as held for sale in 3Q 2024. Sale has been completed in 2Q 2025.


7_


Risk capital figures are group diversified at 99.5% confidence level.


RATING


Ratings1


 

S&P Global


 

Moody’s


 

A.M. Best2


Insurer financial strength rating


 

AA | stable outlook


 

Aa2 | stable outlook


 

A+ | stable outlook


Counterparty credit rating


 

AA | stable outlook


 

Not rated


 

aa3 | stable


Senior unsecured debt rating


 

AA


 

Aa2 | stable outlook


 

aa | stable


Subordinated debt rating


 

A+/A


 

A1/A34 | stable outlook


 

aa- / a+ | stable


Commercial paper (short term) rating


 

A-1+


 

Prime-1


 

Not rated


1


Includes ratings for securities issued by Allianz Finance II B.V. and Allianz Finance Corporation.


2


A.M. Best's Rating Reports reproduced on www.allianz.com appear under licence from A.M. Best Company and do not constitute, either expressly or implicitly, an endorsement of Allianz's products or services. A.M. Best's Rating Reports are the copyright of A.M. Best Company and may not be reproduced or distributed without the express written consent of A.M. Best Company. Visitors to www.allianz.com are authorised to print a single copy of the rating report displayed there for their own use. Any other printing, copying or distribution is strictly prohibited. A.M. Best's ratings are under continual review and subject to change or affirmation. To confirm the current rating visit www.ambest.com.


3


Issuer credit rating.


4


Final ratings vary on the basis of the terms.


 

 


Related links


Media Conference

February 26, 2026, 11:00 AM CET: YouTube (English language)


Analyst Conference

February 26, 2026, 2:00 PM CET: YouTube (English language)


Results

The results and related documents can be found in the download center.


Upcoming events


Annual Report

March 13, 2026


Annual General Meeting

May 7, 2026


Financial Results 1Q 2026

May 13, 2026


More information can be found in the financial calendar.


About Allianz


The Allianz Group is one of the world’s leading insurers and asset managers with around 97 million customers* in nearly 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 764 billion euros** on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 2.0 trillion euros** of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2025, over 156,000 employees achieved total business volume of 186.9 billion euros and an operating profit of 17.4 billion euros for the Group.


*Customer count reflects Allianz customers in consolidated entities that are part of the customer reporting scope only.


** As of December 31, 2025.


These assessments are, as always, subject to the disclaimer provided below.


Cautionary note regarding forward-looking statements


This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.


Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including and related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.


No duty to update


Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.


Other


The figures regarding the net assets, financial position and results of operations have been prepared in conformity with International Financial Reporting Standards. Information is based on preliminary figures. Final results for fiscal year 2025 will be released on March 13, 2026 (publication of the Annual Report). This is a translation of the German Quarterly and Full Year Earnings Release of the Allianz Group. In case of any divergences, the German original is binding.


Privacy Note


Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260225107874/en/



Permalink

https://aetoswire.com/en/news/2602202653553


Contacts

Media contacts

Frank Stoffel Tel. +49 160 9011 5157 e-mail: frank.stoffel@allianz.com

Ann-Kristin Manno Tel. +49 151 2990 1517 e-mail: ann-kristin.manno@allianz.com

Johanna Oltmann Tel. +49 151 1164 6551 e-mail: johanna.oltmann@allianz.com

Fabrizio Tolotti Tel. +49 151 5995 6396 e-mail: fabrizio.tolotti@allianz.com


Investor Relations contacts

Andrew Ritchie Tel. +49 89 3800 3963 e-mail: andrew.ritchie@allianz.com

Reinhard Lahusen Tel. +49 89 3800 17224 e-mail: reinhard.lahusen@allianz.com

Christian Lamprecht Tel. +49 89 3800 3892 e-mail: christian.lamprecht@allianz.com

Tobias Rupp Tel. +49 89 3800 7151 e-mail: tobias.rupp@allianz.com